In the news
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Takara Bio enters into a license agreement of RetroNectin with Fondazione Telethon ETS
Date: September 25, 2023
Categories: Announcement
Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS, Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin.
Automation of Takara Bio’s chemistries on Eppendorf’s automated pipetting systems for significantly higher efficiency
Date: August 28, 2023
Categories: Announcement
Takara Bio Inc. (Takara Bio) and Eppendorf SE, two renowned leaders in the life science industry, are pleased to announce their collaboration through a strategic co-marketing agreement. This partnership aims at jointly developing cutting-edge solutions to automate Takara Bio’s chemistries on Eppendorf epMotion® automation platforms.
Takara Bio is committed to the fight against antimicrobial resistance
Date: December 30, 2022
Categories: Announcement
Access a USA Today article describing solutions that combat the dangerous growth of antimicrobial resistance.
Takara Bio USA, Inc. launches automated, full-length single-cell RNA-seq solution for enhanced biomarker discovery
Date: October 18, 2021
Categories: Announcement
Our complete, automated solution for biomarker discovery enables full-length transcriptome profiling on over 1,500 single cells simultaneously.
Takara Bio Europe SAS launches an in vitro diagnostic assay for the detection of SARS-CoV-2
Date: October 5, 2021
Categories: Announcement
Learn more about Takara Bio Europe's in vitro diagnostic assay for the qualitative RT-qPCR-based detection of novel coronavirus (SARS-CoV-2) from patients suspected of having COVID-19.
Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes
Date: May 6, 2021
Categories: Announcement
The Takara Bio Group of companies and PanCryos are pleased to announce that they have reached a licensing agreement surrounding Takara Bio’s clinical-grade human embryonic stem (hES) cell lines.
Takara Bio licenses CRISPR genome editing technology from MilliporeSigma
Date: December 22, 2020
Categories: Announcement
Takara Bio USA, Inc. and affiliates are excited to announce that we have entered into an agreement with MilliporeSigma to license their CRISPR integration and vector technologies.
Takara Bio congratulates Dr. Christian Hoppmann on CPSA Innovator Award
Date: October 31, 2018
Categories: Announcement
We are pleased and excited to announce that Dr. Christian Hoppmann, Research Scientist at Takara Bio USA, Inc., was awarded an Innovator Award at CPSA USA 2018 following his presentation on Capturem technology.
Takara Bio launches industry-first CMO services for clinical-grade human embryonic stem cell derivation and banking
Date: October 5, 2018
Categories: Announcement
We are excited to be recognized in an article published by the stem cell industry blog BioInformant as the first company in the world to offer contract manufacturing services for the derivation and banking of human embryonic stem cells (hESCs) under GMP conditions.
Takara Bio products are now available on Amazon Business
Date: July 30, 2018
Categories: Announcement
Our products can now be purchased on Amazon using a business account.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2024 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
